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Abstract
Background: Azoxymethane (AOM) or 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis in rats shares
many phenotypical similarities with human sporadic colon cancer and is a reliable model for identifying
chemopreventive agents. Genetic mutations relevant to human colon cancer have been described in this model,
but comprehensive gene expression and genomic analysis have not been reported so far. Therefore, we applied
genome-wide technologies to study variations in gene expression and genomic alterations in DMH-induced colon
cancer in F344 rats.
Methods: For gene expression analysis, 9 tumours (TUM) and their paired normal mucosa (NM) were hybridized
on 4 × 44K Whole rat arrays (Agilent) and selected genes were validated by semi-quantitative RT-PCR. Functional
analysis on microarray data was performed by GenMAPP/MappFinder analysis. Array-comparative genomic
hybridization (a-CGH) was performed on 10 paired TUM-NM samples hybridized on Rat genome arrays 2 × 105K
(Agilent) and the results were analyzed by CGH Analytics (Agilent).
Results: Microarray gene expression analysis showed that Defcr4, Igfbp5, Mmp7, Nos2, S100A8 and S100A9 were
among the most up-regulated genes in tumours (Fold Change (FC) compared with NM: 183, 48, 39, 38, 36 and 32,
respectively), while Slc26a3, Mptx, Retlna and Muc2 were strongly down-regulated (FC: -500; -376, -167, -79,
respectively). Functional analysis showed that pathways controlling cell cycle, protein synthesis, matrix
metalloproteinases, TNFa/NFkB, and inflammatory responses were up-regulated in tumours, while Krebs cycle, the
electron transport chain, and fatty acid beta oxidation were down-regulated. a-CGH analysis showed that four TUM
out of ten had one or two chromosomal aberrations. Importantly, one sample showed a deletion on chromosome
18 including Apc.
Conclusion: The results showed complex gene expression alterations in adenocarcinomas encompassing many
altered pathways. While a-CGH analysis showed a low degree of genomic imbalance, it is interesting to note that
one of the alterations concerned Apc, a key gene in colorectal carcinogenesis. The fact that many of the molecular
alterations described in this study are documented in human colon tumours confirms the relevance of DMH-
induced cancers as a powerful tool for the study of colon carcinogenesis and chemoprevention.
Background
Colorectal cancer is one of the most common neoplas-
tic diseases in the Western World [1], developing
through a multistage process which involves the accu-
mulation of genetic and epigenetic alterations. Experi-
mental models mimicking this disease in rodents, such
as 1,2-dimethylhydrazine (DMH) or azoxymethane
(AOM)-induced carcinogenesis, provide a tool for the
understanding of the molecular alterations arising in
human colon cancer. Inbred strains such as F344 rats,
which are frequently used in these experiments, are
relatively uniform and the tumors developing after
induction show phenotypic and genotypic features
similar to those observed in human sporadic colon
cancers, notably activation of Wnt signaling pathway
and mutations in Kras and Apc genes [2]. Importantly,
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sively in the colon, at variance with other experimental
models in which carcinogenesis develops mainly in the
small intestine, a site rarely involved in human cancer.
Since AOM/DMH tumours are affected by the same
dietary variations known to affect human colon carci-
nogenesis, this model is among the most used and reli-
able for identification of potentially chemopreventive
agents [3].
The advent of genome-wide technologies, such as gene
expression microarray and array-based comparative
genomic hybridization (a-CGH), has provided the possi-
bility to achieve a comprehensive view of the alterations
involved in cancer. Although several papers have been
published on human colon tumours [4] and some also in
AOM-treated mice [5,6], no studies applying genome-
wide technology to DMH-induced cancers in rats have
been reported. Given these considerations, we thought it
of interest to study the gene expression profile of DMH-
induced colon tumours in rats with the 44K Agilent rat
arrays, representing the whole rat genome. Moreover, we
were also interested in studying genomic alterations in
this experimental model. In fact, although genomic
instability in AOM-induced colon cancer in rats was pre-
viously reported [7], the technique in that study (Random
Amplified Polymorphic DNA (RAPD analysis)) did not
give information on the affected loci. On the other hand,
using low resolution comparative genomic hybridization
(CGH) [8], it has also been reported that AOM-induced
tumours in mice have a low level of genomic alterations,
making it difficult to draw any conclusions. Given these
considerations and the possibility of achieving a compre-
hensive view of genomic alterations involved in tumors
with high-resolution genome-wide technologies, we ana-
lyzed DMH-tumours with a-CGH using high resolution
arrays (2 × 105K Agilent rat genome array).
Methods
Tumour induction and harvesting
Briefly, 4- to 5-week old male F344 rats (Nossan, Correz-
zana, Milan, Italy) were fed a high-fat diet based on the
AIN-76 diet as previously described [9]. Rats were housed
according to the European Union Regulations on the Care
and Use of Laboratory Animals [10]; the experimental pro-
tocol was approved by the Commission for Animal Experi-
mentation of the Italian Ministry of Health. At 6-7 weeks
of age rats (n = 14) were treated twice, one week apart,
with subcutaneous injections of 1,2-dimethylhydrazine
(150 mg/kg × 2). Thirty-two weeks after the first DMH
injection, rats were sacrificed by CO2 asphyxiation and
colonic tumors harvested as described [11]. At sacrifice, all
the rats had colon tumours. One-half of each tumour was
cut and stored in RNAlater (Qiagen) while the second half
was fixed in buffered formalin for histopathological and
immunohistochemical analysis as described [11]. Apparent
normal mucosa from each rat was also scraped from the
colon and stored in RNAlater (Qiagen) before DNA or
RNA extraction.
Histological analysis
Histological sections of each tumour were stained with
hematoxylin and eosin to confirm the presence and type
of tumours by histopathological examination, on the
basis of the histotype, grading and pattern of growth as
described [11].
Microarray hybridization
RNA isolation, labeling, hybridization and image analysis
Total RNA was extracted from 9 paired samples of nor-
mal mucosa (NM) and adenocarcinomas (TUM) using
the RNeasy Midi kit (Qiagen, Milan, Italy). For each
hybridization, 18 μg of total RNA from each sample (NM
or TUM) was used. Each TUM (labeled with Cy5)
(CyDye Mono-Reactive Dye Pack, Amersham, Cologno
Monzese, Milan, Italy) was individually hybridized on
Agilent Whole Rat Genome 4 × 44K microarrays (Agilent
Technologies, Palo Alto, CA, USA) using the RNA
(labeled with Cy3) from the corresponding NM as refer-
ence. As for labeling, we used the indirect labeling
method described previously[ 1 2 ] .T h eh y b r i d i z a t i o n
steps were carried out according to the Agilent protocol
and images were scanned using a Genepix 4000B micro-
array scanner (Axon Instruments, Foster City, CA, USA).
Image analysis and initial quality control were performed
using Agilent Feature Extraction Software v9.5.
Microarray data analysis
The text files were imported into R 2.5.1 using the Bio-
conductor “limma” package 2.8.1 for statistical analysis
as reported [13]. Values for control spots and spots that
d i dn o tm e e tt h eq u a l i t yc r i t e r i aw e r ef l a g g e d .Q u a l i t y
criteria included a minimal spot size, a median/mean
ratio of at least 0.9 for each spot, non-saturated intensity
for both channels, a signal well above background and a
minimal signal intensity for at least one channel. Due to
the high number of features that did not meet the qual-
ity control criteria, one out of the nine hybridizations
was excluded from subsequent analysis. The back-
ground-corrected intensities of all microarrays were nor-
malized using the LOESS algorithm as reported [13].
The tumour samples were compared to the correspond-
ing normal mucosa using a paired moderated t-test with
the Benjamini-Hochberg correction of the FDR (false
discovery rate) for the multiple tests [14].
Functional analysis
Biological pathway analysis was performed using the
GenMAPP/MAPPFinder software tandem [15]. For
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the “Rn_20080619” pathway set were used. MAPPFinder
analyses for pathway enrichment were performed for
up- and down-regulated genes, separately. MAPPFinder
selection criteria were set at Benjamin-Hochberg p <
0.05. Only statistically significant pathways showing
a permuted p-value < 0.05 and a positive (enrichment)
z-score >2 were selected.
Semi-quantitative RT-PCR
One microgram of total RNA for each sample (tumour
and normal mucosa) was reverse transcribed using 100
units of SuperScript™ II Reverse Transcriptase (Life
Technologies, Milan, Italy) and 1× random hexamers
(Roche Diagnostics, Monza, Italy). Seven out of the 9
paired TUM-NM samples were processed for RT-PCR
analysis. The following genes were tested: Defcr4,
S100A9, Igfbp5, Slc30a2 and Lrg5 (up-regulated genes);
Mptx, Slc26a3, Retnla, Hpgd and Muc2 (down-regulated
genes). The list of the primers used is provided in the
Additional file 1: List of the primers used for semi-
quantitative RT-PCR. Each gene was co-amplified with
b-actin gene (Actb) as internal control as described [16].
PCRs were carried out using cDNA aliquots in a 25 μl
total volume containing 1× PCR buffer, 2 mM MgCl2,
0.5 mM dNTPs, and 1.25 units of Taq polymerase
(Sigma-Aldrich, Italy). Primers for each gene were also
added (concentration range: 0.16 - 0.4 μM), together
with the primers for b-actin (concentration range:
0.015-0.04 μM). The PCR conditions were: 95°C for 7
min and then 35 cycles at 95°C for 30 sec, 60°C for 30
sec and 72°C for 55 sec and a final extension at 72°C
for 5 min. The PCR products were separated on 1.6%
agarose gel, visualized by ethidium bromide staining.
Gel images were captured by a digital photocamera
(UviDoc) and the intensity of the bands was analyzed
with Quantity-One software (Bio-Rad, Segrate, Milan,
Italy). A t-test for paired samples was used to compare
normal mucosa and tumor expression as previously
described [16].
Array-comparative genomic hybridization
A different set of ten samples of paired TUM-NM har-
vested from the same 14 rats was used to explore the
presence of genomic aberrations in DMH-induced ade-
nocarcinomas. To this purpose, genomic DNA was
extracted by the DNeasy Tissue kit (Qiagen) and each
tumour was hybridized on Agilent Rat Genome CGH
Microarray 2 × 105K, following the Agilent protocol,
using the corresponding normal mucosa as reference.
The Rat CGH Agilent arrays contain 97,973 coding and
noncoding sequences with an average probe spatial reso-
lution of 19.1 Kb allowing high resolution analysis of the
rat genome. Slides were scanned using the Genepix
4000B microarray scanner (Axon Instruments, Foster
City, CA, USA). Image analysis and initial quality con-
trol were performed using Agilent Feature Extraction
Software v9.5. Feature Extraction files were then loaded
into CGH Analytics 3.5.14 software (Agilent Technolo-
gies, Palo Alto, CA, USA) and analyzed for aberration
calls by selecting as follows: algorithm ADM-2, centrali-
zation on, fuzzy zero on, threshold at 6.0, aberration fil-
ter set at 5 for the minimum number of probes in
region and at 0.24 for the minimum absolute average
log ratio for region. The Derivative Log Ratio Spread
(DLRS) for the ten hybridizations was in the range 0.11-
0.24. The Rat genome sequence used was the Rn4
version.
Immunohistochemical analysis
Tumour sections from 6 adenocarcinomas were pro-
cessed for immunohistochemistry as described [11],
using as primary antibody a rabbit polyclonal antibody
against NFkB/p65 (Thermo Fisher Scientific, Fremont,
CA) diluted 1:100 in PBS containing 1% bovine serum
albumin and incubated for 1 h at room temperature
(RT). The slides were processed with Biotinylated Goat
Anti-Polyvalent as the secondary antibody (LAB Vision
Corporation, CA, USA), and then weakly counterstained
with Harris’s hematoxylin [11]. Negative controls in
which the primary antibody was omitted were per-
formed in each experiment.
Results
The analyses described in this paper were carried out in
colon cancers harvested from 14 rats induced with
DMH as described in the Methods. The mean number
of total tumours (both adenomas and cancers)/rat was
2.5 ± 0.34 (SD); adenomas/rat were 1.14 ± 1.09 while
cancers/rat were 1.36 ± 0.49; all rats developed tumours.
All the cancers analyzed (n = 19) were adenocarcinomas
(Fig. 1D), except for one that was a mucinous adenocar-
cinoma (sample #14). Two samples were graded as
moderately differentiated (samples #2 and #14), while
the remaining 17 samples were well differentiated
cancers.
Gene expression profile by microarray analysis
Nine colon adenocarcinomas were hybridized on Agilent
microarrays and each compared with its respective nor-
mal mucosa (NM). Eight out of nine of these samples
passed the quality control step and were then analyzed
as described in detail in the Methods section. Of the
about 41,000 genes and transcripts present in the 4 ×
44K Agilent Rat Whole Genome Expression slides,
27,329 probes passed the quality control step. The com-
plete list of these 27,329 gene probes is provided as
Additional file 2: Complete microarray gene expression
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adenocarcinomas. This list also comprises the 15,251
significantly up- or down-regulated gene probes as
determined by statistical analysis (see the column with
heading adjPVal).
Hierarchical clustering analysis of the eight array
expression data (n = 8) shows a homogenous expression
profile among these samples (Additional file 3: Hierarch-
ical clustering analysis of gene expression data).
Setting a filter to a fold change (FC) equal to ± 10, we
found that 266 (1%) and 566 (2%) genes were signifi-
cantly up- or down-regulated in tumours vs NM, respec-
tively (see Additional file 2). Moreover, using a FC
cut-off equal to ± 2, 3724 (13.6%) and 3750 (13.7%) genes
were significantly up- and down-regulated in tumors,
respectively (see Additional file 2). Table 1 shows the
first 25 up-regulated genes in tumours; among these, we
found Defcr4 (defensin-related cryptdin 4), Slc30a2
Figure 1 Immunohistochemistry for NFkB/p65 and histology in a DMH-induced cancer. Panel A: adenocarcinoma sample challenged with
an antibody against NFkB/p65. Panel B: magnification of the inset in panel A; note that positive cells in the tumour show immunoreactivity in
both the cytoplasm and the nucleus. Panel C: paired normal mucosa of the tumor challenged with the same antibody. Panel D: H&E stained
section of the same tumour. Original magnification in panels A and C: ×400, panel B: ×1000, panel D: ×100.
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Page 4 of 13Table 1 List of the first 25 genes up- and down-regulated in tumours.
Gene name Gene Description [Accession number] FC
Up-regulated
Defcr4 Defensin related cryptdin 4 [NM_001013053] 183.2
Slc30a2 Solute carrier family 30 (zinc transporter), member 2 [NM_012890] 71.7
Lum Lumican [NM_031050] 70.0
Mmp12 Matrix metallopeptidase 12 [NM_053963] 65.1
Iggc Immunoglobulin gamma2a constant region [DQ402472] 58.8
Hoxd13_predicted Homeo box D13 (predicted) [XM_221511] 50.5
Igfbp5 Insulin-like growth factor binding protein 5 [BC087030] 48.4
CB548350 Tenascin C [CB548350] 47.0
Msr2_predicted Macrophage scavenger receptor 2 (predicted) [XM_227485] 45.7
Mx2 Myxovirus (influenza virus) resistance 2 [NM_134350] 43.9
Aldh1a3 Aldehyde dehydrogenase family 1, subfamily A3 [NM_153300] 42.8
Cxcl2 Chemokine (C-X-C motif) ligand 2 [NM_053647] 39.9
Mmp7 Matrix metallopeptidase 7 [NM_012864] 39.4
Nos2 Nitric oxide synthase 2, inducible [NM_012611] 38.1
S100a8 S100 calcium binding protein A8 (calgranulin A) [NM_053822] 36.2
Igfbp7 Insulin-like growth factor binding protein 7 [XM_214014] 35.8
Col12a1 PREDICTED: procollagen, type XII, alpha 1 [XM_243912] 35.7
Plod2 Procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 [NM_175869] 33.4
S100a9 S100 calcium binding protein A9 (calgranulin B) [NM_053587] 31.9
Ctgf Connective tissue growth factor [NM_022266] 31.5
Fn1 Fibronectin 1 [NM_019143] 31.4
T_predicted T, brachyury homolog (mouse) (predicted) [XM_217890] 30.0
Sparc Secreted acidic cysteine rich glycoprotein [NM_012656] 29.6
Cyp26b1 Cytochrome P450, family 26, subfamily b, polypeptide 1 [NM_181087] 29.4
Nkd1_predicted Naked cuticle 1 homolog (Drosophila) (predicted) [XM_001066780] 29.1
Down-regulated
Slc26a3 Solute carrier family 26, member 3 [NM_053755] -502.6
Mptx Mucosal pentraxin [NM_001037642] -376.5
Retnla Resistin like alpha [NM_053333] -166.9
Zg16 Zymogen granule protein 16 [NM_134409] -105.3
Clca3_predicted Chloride channel calcium activated 3 (predicted) [XM_217689] -99.1
Grap GRB2-related adaptor protein [NM_001025749] -95.2
Fabp1 Fatty acid binding protein 1, liver [NM_012556] -94.7
Ceacam20_predicted CEA-related cell adhesion molecule 20 (predicted) [XM_218430] -92.8
Dpep1 Dipeptidase 1 (renal) [NM_053591] -90.9
Pbp2 Phosphatidylethanlomine binding protein 2 [XM_575702] -90.4
B4 galt2_predicted UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 2 (predicted) [XM_242992] -90.0
Apoa1 Apolipoprotein A-I [NM_012738] -80.6
Olr1611_predicted Olfactory receptor 1611 (predicted) [XM_223954] -80.5
Dmbt1 PREDICTED: deleted in malignant brain tumours 1 (Dmbt1), [XM_577842] -80.0
Muc2 Mucin 2 [U07615] -78.7
Trpm5_predicted Transient receptor potential cation channel, subfamily M, member 5 (predicted) [XM_344979] -73.1
Chia Rattus norvegicus chitinase, acidic [NM_207586] -72.7
Kb15 Type II keratin Kb15 [XM_345877] -72.6
Gpr156 G protein-coupled receptor 156 [NM_153295] -71.8
Pdha2 Pyruvate dehydrogenase E1 alpha 2 [NM_053994] -71.3
Hspa1l_mapped Heat shock 70 kD protein 1-like (mapped) [NM_212546] -71.0
Pcdhb13 PREDICTED: Protocadherin beta 13 [XM_001055698] -71.0
Pcsk4 Proprotein convertase subtilisin/kexin type 4 [NM_133559] -70.4
Masp1 Mannan-binding lectin serine peptidase 1 [NM_022257] -70.4
C1ql1_predicted Complement component 1, q subcomponent-like 1 (predicted) [XM_343971] -70.3
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can, a member of a small leucine-rich proteoglycan
family), Mmp12 (matrix metallopeptidase 12), Igfbp5
(insulin growth factor binding protein 5), Mmp7 (matrix
metallopeptidase 7), Nos2 (nitric oxide synthase 2, indu-
cible), S100A8 (S100 calcium binding protein A8 (calgra-
nulin A)) and S100A9 (S100 calcium binding protein A9
(calgranulin B)). Among the most down-regulated genes
(Table 1), we found Slc26a3 (solute carrier family 26,
member 3, also known as down-regulated in adenoma
(Dra)), Mptx (mucosal pentraxin), Retnla (resistin like-
a), Muc2 (mucin 2). For a selected group of genes, the
results obtained with microarray analysis were confirmed
by semi-quantitative RT-PCR. These were Defcr4,
S100A9, Igfbp5, Slc30a2 and Lgr5 (leucine-rich repeat
containing G protein coupled receptor 5) which were up-
regulated and Mptx, Slc26a3, Retnla, Muc2 and Hpgd
(hydroxyprostaglandin dehydrogenase 15) which were
down-regulated in tumours (Fig. 2).
To understand whether specific biological pathways or
functional groups of genes were differentially affected in
tumours, we analyzed our microarray data set using the
Gen MaPP/MappFinder software tool. The results of
this analysis showed that 17 pathways were significantly
up-regulated in tumours, while 10 were down-regulated
(Table 2). The list of genes present in these significantly
up- or down-regulated pathways is shown in Additional
files 4 and 5 (Additional file 4: List of the genes belong-
ing to the significantly up-regulated pathways; Addi-
tional file 5: List of the genes belonging to the
significantly down-regulated pathways). Among the up-
regulated pathways we found those related to cell cycle,
to RNA and protein metabolism, to extracellular matrix
remodeling.
Moreover, since the results of this analysis also
pointed out an up-regulation of the inflammatory pro-
cesses (inflammatory response pathway, TNFa-NFkB,
complement activation), we further investigated the
involvement of the NFkB pathway, determining in six
adenocarcinomas the expression of RelA (p65) with
immunohistochemistry. The results (Fig.1, panels A-C)
showed that p65, a key member of the NFkB pathway,
was highly expressed in the tumours compared to nor-
mal mucosa.
Among the pathways and grouping of functional genes
down-regulated in tumors (Table 2) we found those
Figure 2 Semi-quantitative RT-PCR analysis of ten selected genes. For each up-regulated (first five rows) or down-regulated (last five rows)
genes, three representative gel images of paired normal mucosa (N) and tumour (T) were provided. For each RT-PCR experiment, expression of
b-actin was used as an internal control. P values refer to the t-test for paired samples (n = 7) to compare tumours with normal mucosa.
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Krebs-tricarboxylic acid cycle and electron transport
chain) and nuclear receptors.
Genomic alterations by a-CGH
An additional set of ten colon adenocarcinomas har-
vested from the same rats were analyzed by a-CGH,
comparing each tumour sample with its respective nor-
mal mucosa (NM). All the hybridized arrays passed the
quality control step and were then analyzed by the
CGH Analytics 3.5 software (Agilent Technologies) for
detection of chromosomal aberrations. In the 10
tumors analyzed, a total of 6 alterations were observed
in four tumours (Table 3). Four of these 6 aberrations
were amplifications (length of the amplified regions
ranged from 67 to 2135 kb) and two were deletions
(672 kb and 1362 kb, respectively). Two tumours (sam-
ples #3 and #5) showed two aberrations each (two
amplifications in tumour #3 and one amplification plus
a deletion in tumour #5), while the remaining two
samples had only one aberration each.
The genomic aberrations were located in a region of
chromosome 1, amplified in one tumor containing
Pcsk6, coding for a protease belonging to the pro-pro-
tein convertase family. The same tumour carrying this
amplification also carried a long amplification on chro-
mosome 7 with more than forty genes mapping in this
region (Table 3). Contrary to the long amplification of
chromosome 7, the deletion on the same chromosome
carried by a different tumour was short, with only two
genes (Nudt4 and Ac1-114) mapping in this region.
Notably, in tumour sample #9, we observed an intersti-
tial deletion of 1.36 Mb on chromosome 18 encompass-
ing the Apc (Adenomatous polyposis coli) gene as well as
other genes such as Catna1 (coding for b-catenin)
(Table 3 and Fig. 3).
Table 2 Pathways or functional groups of genes differentially expressed in tumours by GenMapp/MappFinder
analysis*.
MAPP Name Number Changed Number Measured Number On MAPP Z Score
Up-regulated pathways or functional group of genes
Rn_DNA_replication_Reactome 17 22 40 3.289
Rn_Matrix_Metalloproteinases 12 13 28 3.621
Rn_TNF-alpha-NF-kB_NetPath_9 69 117 159 3.648
Rn_G1_to_S_cell_cycle_Reactome 29 40 69 3.838
Rn_mRNA_processing_Reactome 44 66 125 3.988
Rn_Translation_Factors 24 29 40 4.383
Rn_Ribosomal_Proteins 65 74 81 7.979
Rn_Cell_cycle_KEGG 32 49 80 3.227
Rn_RNA_transcription_Reactome 15 19 41 3.202
Rn_TGF_Beta_Signaling_Pathway 27 39 45 3.372
Rn_Inflammatory_Response_Pathway 16 22 40 2.855
Rn_Proteasome_Degradation 27 42 53 2.848
Rn_Alpha6-Beta4-Integrin_NetPath_1 29 47 64 2.654
Rn_B_Cell_Receptor_NetPath_12 61 112 146 2.573
Rn_Signaling_of_Hepatocyte_Growth_Factor_Receptor_Biocarta 18 27 33 2.527
Rn_Nucleotide_Metabolism 10 14 17 2.175
Rn_Complement_Activation_Classical 7 9 14 2.127
Down-regulated pathways or functional group of genes
Rn_Nuclear_Receptors 16 26 37 3.564
Rn_Unsaturated_Fatty_Acid_Beta_Oxidation_BiGCaT 6 6 6 3.766
Rn_Electron_Transport_Chain 26 44 58 4.298
Rn_Nuclear_receptors_in_lipid_metabolism_and_toxicity 13 19 33 3.700
Rn_Fatty_Acid_Beta_Oxidation_2_BiGCaT 5 6 6 2.873
Rn_Krebs-TCA_Cycle 12 23 26 2.362
Rn_Irinotecan_pathway_PharmGKB 5 6 12 2.873
Rn_Peptide_GPCRs 15 31 62 2.283
Rn_Calcium_regulation_in_cardiac_cells 41 102 150 2.360
Rn_Glucocorticoid_Mineralocorticoid_Metabolism 5 7 9 2.414
* Significantly enriched pathways (z-score >2) are listed. The different columns show the number of genes differentially expressed compared with normal
mucosa, the number of genes analyzed and the number of genes listed in each map (http://www.genmapp.org; University of California at San Francisco,
San Francisco, CA, USA)
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This is the first report describing variations in gene
expression and genomic alterations in DMH-induced rat
colon adenocarcinomas using microarray technologies.
We found that many transcripts were differentially
expressed in colon tumors, 7400 of them being differen-
tially expressed in tumours with a FC ≥ 2 [3724 (13.6%)
and 3750 (13.7%) up-regulated or down-regulated in
tumours].
The most up-regulated gene was Defcr4,a l s ok n o w n
as enteric defensin a5, belonging to the family of the a-
defensin antimicrobial peptides secreted by Paneth cells
[17]. Other markers of Paneth cells such as defensin
alpha 6 (Defa6; FC = 18.7), matrix metallopeptidase
Table 3 Summary of the chromosomal aberrations found in adenocarcinomas from DMH-induced rats.
Tumour Aberration Chromosome Aberration
length (kb)
Genes in the aberrant region
# 3 Amplification 1q22 109.8 Pcsk
Amplification 7q11 2135.3 Sirt6, Tle2, Aes, Gna11, Gna15, Ncln, NF1-C2, Tbxa2r, Pip5k1c, Apba3, Matk, Atcay_predicted,
Dapk3, Zbtb7a, Map2k2, Creb3l3, Thop1, Sgta, Slc39a3, Gng7, Gadd45b, Tmprss9_predicted,
RGD1308556, Sf3a2, Mknk2, Csnk1 g2, Scamp4, RGD1359682, Tcfe2a, Reep6, Pcsk4, Dazap1,
Cirbp, Abca7, Grin3b, Prtn3_predicted, Prg-2, Ptbp1, Palm, Fstl3, Rnf126, Hcn2, Bsg,
# 5 Deletion 7q13 671.9 Nudt4, Ac1-114
Amplification 2q23 66.9 LOC360689
# 6 Amplification 15q22 189.4 Unknown
# 9 Deletion 18 p11-12 1362.1 Apc, Brd8, Gfra3, Egr1, Etf1, Catna1, Sil1
Figure 3 CGH analytics chromosome view of a region of chromosome 18 of all tumor samples analyzed. Colored curves represent Log2
ratio values for all nucleotide probes plotted as a function of their chromosomal position for each tumor sample. Thick straight vertical blue line
and blue shaded area point out a deletion present in sample #9. The black arrow indicates the Apc gene position.
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pholipaseA2 (Pla2 g2a; FC = 20), were also up-regulated
in our samples, suggesting that these cells are a cellular
component of colon tumours, in agreement with pre-
vious reports [17-19]. Although it has been suggested
that the presence of Paneth cells in colon cancer is a
fortuitous consequence of the Wnt pathway activation
[17,20], it is interesting to note that Mmp7 up-regula-
tion, as observed in our samples, has been correlated
with metastasis and apoptosis resistance in cancer [21].
Besides Mmp7, other metalloproteinases (MMPs)
involved in the degradation of extracellular matrix in
the late phases of carcinogenesis were up-regulated in
our samples (Mmp3, 9, 10, 12 and 14; FC = 4.3, 18.1,
13.1, 65.1, 3.2, respectively) (see also Additional file 2)
[18], a result reinforced by the significant up-regulation
of the MMP pathway pointed out by GenMapp analysis.
Linked to MMPs in the process of invasion, we also
found up-regulation of genes involved in the urokinase-
type plasminogen activator system such as urokinase-
plasminogen activator u-PA (Plau in rat; FC = 9.6),
u-PA receptor (Plaur; FC = 2) and plasminogen (Plg; FC
= 13.6) (see Additional file 2) [22]. Interestingly, it has
also been suggested that u-PA might catalyze the activa-
tion of the mesenchymal-derived cytokine hepatocyte
growth factor/Scatter Factor (HGF/SF), thus facilitating
invasiveness [22,23], an observation in line with the acti-
vation of HGF signaling in our tumours, as pointed out
by the GenMapp analysis.
Slc30a2, the second most up-regulated gene in our set
of colon adenocarcinomas, codes for the protein Znt2
which has been reported to promote zinc efflux into
intracellular vesicles when Zn concentration rises in the
cell [24]. Accordingly, a previous study showed that Zn
concentration was higher in rat colon tumours than in
normal mucosa [25].
The Lum gene, coding for the protein Lumican, is
the third most expressed gene in our set of tumours
(Table 1). Lumican plays an important role in collagen
fibrillogenesis and its over-expression has been
reported in human colorectal cancer [26]. Another
dramatically up-regulated gene in our samples is
Igfbp5 (Insulin-like growth factor-binding protein 5)
(Table 1), a component of the IGF axis [27], implicated
in colon carcinogenesis with contradictory results
[28,29]. Indeed, while Igfbp5 is up regulated in adeno-
mas from Apc
Min/+ mice, it moves in the opposite
direction in human colorectal cancers and cancer cell
lines [28]. It has also been shown that IGFBP5 can be
cleaved by MMP7 forming IGF-II which in turn can
act as a growth factor for colonic myofibroblasts [29],
suggesting an important role for IGFBP5 and MMP-7
in the tumoural epithelial-mesenchymal transition.
Recent evidence also indicates that Igfbp5 may act as a
tumour suppressor by inhibiting angiogenesis [30].
These results suggest the need to further investigate
t h er o l eo fIgfbp5 in colon cancers.
Among the most up-regulated genes we also found
Nos2 (Table 1) coding for the pro-inflammatory enzyme
inducible nitric oxide synthase (i-NOS). Many reports
document high i-NOS activity in colorectal cancers
[31,32]; recently, we also reported that DMH-induced
colorectal tumours have highi - N O Se x p r e s s i o n[ 3 3 ] .
Interestingly, S100A8 and S100A9, whose products form
the heterocomplex calprotectin, are strongly up-regulated
in our study (Table 1), in agreement with reports on
inflammation-associated cancer and in human colorectal
carcinomas [34,35]. Accordingly, we also observed an up-
regulation of genes involved in prostaglandin synthesis,
such as cyclooxygenase 1 and 2 (Ptgs1 and Ptgs2; FC =
5.4 for both genes, see Additional file 2) and prostaglan-
din E synthase (Ptges; FC = 2.2) associated with strong
down-regulation of the gene for the enzyme degrading
prostaglandins (15-hydroxyprostaglandin dehydrogenase,
Hpgd; FC = -29), as demonstrated in both the array and
RT-PCR experiments and in agreement with previous
reports showing a down-regulation of this gene in colon
carcinogenesis [36]. Moreover, GenMapp analysis
pointed out that the TNFa-NF-kB pathway was up-
regulated in our samples, as also demonstrated by the
over-expression of p65 (RelA) observed with both immu-
nohistochemistry (Fig.1, panels A-C) and array technique
(FC of RelA: 2.2, see additional file 2). All these data con-
firm that DMH-induced tumours show activation of
inflammatory process pathways, as documented in rats
and human colon cancer [32,33,37].
Aberrant activation of the Wnt signaling has been
demonstrated in both experimental and human carcino-
genesis [38]. Accordingly, many Wnt-target genes were
up-regulated in our samples (Ccnd2 (FC = 5.9), Lef1
(FC = 21.5), Mmp7, Axin2 (FC = 3.9), CD44 (FC = 3.4),
Bmp4 (FC = 5.1), Dkk3 (FC = 14.3), Sox9 (FC = 2.9),
Fn1 (FC = 31.4), Mmp9 (FC = 18.1), Stra6 (FC = 21.3),
Ptgs2 (FC = 5.4), Postn (FC = 11.8), Sfrp2 (FC = 6.3))
[39] (see also Additional file 2). Notably, Lgr5,am a r k e r
of stem cells in colon epithelium [18] was also up-regu-
lated in the arrays (FC = 10) as well as in RT-PCR
experiments, demonstrating that cells presenting this
stem marker are over-represented not only in Min mice
intestinal tumours and human colon cancers [40,41],
but also in DMH-induced colonic tumors.
As expected, we also found an up-regulation of path-
ways related to nucleotide metabolism, DNA replication,
cytoplasmic ribosomal protein, translation factors, pro-
teasome degradation, mRNA processing and cell cycle
(Table 2).
On the contrary, the up-regulation of the TGF-b path-
way in our samples was somewhat unexpected since
Femia et al. BMC Cancer 2010, 10:194
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of TGF-b signaling [42-44]. In our samples the genes
coding for the ligand Tgfb1 (FC = 5.7), the receptors
Tgfrb1 (FC = 2.6) and Tgfrb2 (FC = 5.5) as well as
Smad2 (FC = 2.9) and Smad4 (FC = 2.4) were up-regu-
lated, although not Smad3 (FC = -2.3) which was down-
regulated. It is interesting to note that although TGF-b
is a potent inhibitor of normal colonic epithelial cells, it
can also promote the survival, invasion and metastasis
of colorectal cancer cells, thereby acting as an oncogene,
a paradoxical role which could explain our results
[45,46].
Slc26a3, coding for a Cl(-)/HCO(3)(-) exchanger, is
the most down-regulated gene in this report. Although
genetic studies linked mutations in the homologous
human gene (SLC26A3) to congenital chloride-losing
diarrhea, it is interesting to note that Slc26a3 is also
known with the alias “down-regulated in adenoma”
(Dra), since it was first identified as a gene strongly
down-regulated in colon adenomas and adenocarcino-
mas [47,48]. Its deficiency has been associated with an
increase in cellular proliferation [48], a feature that
could partly contribute to tumour development also in
our samples. Mptx, the gene coding for mucosal rat
pentraxin, is also strongly down-regulated in the present
study. Mptx was first described as the most down-regu-
lated gene in the colonic mucosa of rats fed dietary
heme and, since it has been suggested to play a role in
the clearance of dying cells, its down-regulation could
lead to a reduced apoptosis ability, another characteristic
of tumour cells [49]. Retlna (resistin-like molecule a),
which is also down-regulated in our samples (Table 1
and Fig. 2), belongs to a family of resistin-like molecules
implicated in metabolism, energy balance and intestinal
inflammation [50].
We also observed a strong down-regulation of the
Muc2 gene, coding for Muc2, the most abundant mucin
secreted by normal colonocytes, in agreement with
experimental and clinical reports documenting defective
mucin production in colorectal cancer [51,52].
Significantly down-regulated pathways were processes
such as Krebs-TCA-cycle, electron transport chain, and
fatty acid beta-oxidation (Table 2), in agreement with
many previous observations showing a metabolic repro-
gramming of the cancer cell favoring glycolysis even in
the presence of oxygen [53].
It has also to be noted that our rats were fed a high-
fat diet containing 23% corn oil as a source of fat, a diet
currently used in our laboratory since it closely mimics
the high-fat diet typical of western countries with popu-
lations having a high incidence of colon cancer. Thus
one could wonder whether the same results would be
observed also in animals fed a low-fat diet. However,
since in our experiments we compared tumours with
their paired normal mucosa, it is not possible to infer
the influence of diet on gene expression profile in
tumours. In fact, to carefully address this issue, one
would have to perform an additional experiment com-
paring the tumour profile from low-fat diet rats with
that from high-fat diet rats.
In the present study we also evaluated genomic altera-
tions with a-CGH analysis in a different set of tumours
harvested from the same rats. This is, to our knowledge,
the first attempt to highlight genomic aberrations in
DMH-induced colonic tumours in the rat by means of
high resolution a-CGH.
Our results show that genomic aberrations are rela-
tively infrequent, with 40% of tumours showing only
one or two aberrations (i.e. amplification or deletion),
while the remaining 60% show a stable genome. The
detected alterations spanned from 66 to 2135 kb and in
no case did we observe gains or losses of whole chromo-
somes. The relatively low level of genomic alterations in
this study is in agreement with previous reports on
tumours from Min mice and AOM-treated A/J mice
[8,54]. In a previous study from our laboratory, we
reported frequent genomic alterations in AOM-induced
colon tumours using RAPD analysis [7]; this discrepancy
might be due to the fact that high-resolution a-CGH, at
variance with RAPD, does not detect small alterations
(such as single base mutations), which could be frequent
in this model.
Notably, one of the aberrations found in the present
study was a deletion on chromosome 18, spanning a
1362 kb region containing the Apc gene, a key gene in
colon cancer [38]. Previously, we demonstrated that
DMH-induced colon cancers, beside mutations in
Ctnnb1 (coding for b-catenin) and Kras, carry single-
nucleotide mutations in Apc with a frequency of about
30% [2]. Therefore, the occurrence of an interstitial
deletion encompassing this gene could be a further
mechanism of Apc inactivation in colon carcinogenesis.
Accordingly, allelic loss of one APC gene copy without
detectable APC mutation has been reported in human
colorectal tumours [55]. It is also interesting to note
that among the genes mapping in the region deleted in
this sample, we found Catna1 (coding for b-catenin).
Unlike b-catenin, the contribution of a-catenin to col-
orectal carcinogenesis is controversial [56]. In fact
some reports suggest that a-catenin is essential for
tumour formation [56], while others suggest that a-
catenin plays a tumour-suppressive role in the late
stages of colorectal carcinogenesis [57,58]. Notably all
the genes deleted on chromosome 18 (including Apc
and Catna1), are synthenic with their human homolo-
gues genes (i.e. they are also close to each other in the
human genome, all of them mapping on the short arm
of chromosome 5).
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In conclusion, we have used genome-wide technologies
to study the gene expression profile and genomic altera-
tions in DMH-induced colon cancers, for which no
information was previously available. Our results show
complex gene expression alterations in adenocarcinomas
encompassing many altered pathways such as those
linked to inflammation, matrix metalloproteases, cell
proliferation and metabolism. While a-CGH analysis
showed a low degree of genomic imbalance in these
tumours, it is interesting to note that one of the altera-
tions found regards Apc, a key gene in colorectal carci-
nogenesis. The fact that many of the alterations
described in this study are documented in human colon
tumours confirms the relevance of DMH-induced can-
cers as a powerful tool for the study of colon carcino-
genesis and chemoprevention. Moreover, the results of
this study encompassing the characterization of genomic
alterations in colon adenocarcinomas may serve as the
basis for investigations of the derangements occurring in
the early phases of colon carcinogenesis, which are
easily analyzed using this model.
Additional file 1: List of the primers used in the RT-PCR
experiments. The file provides the sequences of the primers used for
reverse-transcriptase-PCR experiments and the GenBank accession
number for each gene.
Additional file 2: Complete microarray gene expression data from
the comparison between normal colon mucosa and
adenocarcinomas. The file provides the complete list of the 27,329
probes passing the quality control step as described in the methods. For
each probe, the Agilent probe name, gene name, gene identifier,
EntrezGene ID http://www.ncbi.nlm.nih.gov/gene, Log10 fold change (FC),
FC and adjusted P value is reported. The fold changes are means of at
least 4 out of 8 colon cancers. AdjPval < 0.05 identifies genes
differentially expressed in cancers compared to the corresponding NM.
Additional file 3: Hierarchical cluster analysis of gene expression
data. Hierarchical cluster analysis of gene expression data from the 8
DMH-induced tumours (samples # 11-18) compared to the
corresponding normal colon mucosa. The analysis was performed on all
genes which passed the quality control step present in 100% of the
experiments.
Additional file 4: List of the genes belonging to the significantly
up-regulated pathways. List of the genes (EntrezGene ID: http://www.
ncbi.nlm.nih.gov/gene) belonging to the significantly up-regulated
pathways shown in Table 2.
Additional file 5: List of the genes belonging to the significantly
down-regulated pathways. List of the genes (EntrezGene ID: http://
www.ncbi.nlm.nih.gov/gene) belonging to the significantly down-
regulated pathways shown in Table 2.
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